Global MPNST registry aims to unlock secrets of rare nerve cancer
NCT ID NCT03141021
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is building a worldwide database of people with malignant peripheral nerve sheath tumors (MPNST), a rare cancer often linked to the genetic condition neurofibromatosis type 1. Researchers will collect medical records, tumor samples, and genetic data to find patterns that could improve diagnosis and treatment. The goal is to better understand the disease, not to test a new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
WITHDRAWNBoston, Massachusetts, 02215, United States
-
Global Gene Corporation
COMPLETEDMumbai, India
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21205, United States
-
Lifespan
COMPLETEDProvidence, Rhode Island, 02903, United States
-
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITINGNew York, New York, 10065, United States
-
Moffitt Cancer Center
COMPLETEDTampa, Florida, 33612, United States
-
Mount Sinai
RECRUITINGToronto, Ontario, M5T 3L9, Canada
-
Nagoya University Hospital
RECRUITINGNagoya, Showa Ward, Japan
-
National Institutes of Health (NIH)
NOT_YET_RECRUITINGBethesda, Maryland, 20892, United States
-
Royal National Orthopedic Hospital
TERMINATEDLondon, United Kingdom
-
University of Minnesota
WITHDRAWNMinneapolis, Minnesota, 55455, United States
-
University of Utah
COMPLETEDSalt Lake City, Utah, 84112, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo shows promise for rare nerve tumors
- New drug targets rare nerve tumors in people with specific gene loss
- Blood test could spot rare nerve tumors years earlier in NF1 patients
- Engineered immune cells take aim at childhood cancers in early trial
- Engineered immune cells take on childhood cancers in first human test
- Engineered immune cells take aim at childhood cancers